

**(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)**

**(19) World Intellectual Property Organization**  
International Bureau



**(43) International Publication Date**  
**31 October 2002 (31.10.2002)**

PCT

**(10) International Publication Number**  
**WO 02/086114 A1**

**(51) International Patent Classification<sup>7</sup>:** **C12N 9/02,**  
A21D 8/04, C12P 7/64, C12N 15/63, C11D 3/386

**(21) International Application Number:** PCT/DK02/00251

**(22) International Filing Date:** 18 April 2002 (18.04.2002)

**(25) Filing Language:** English

**(26) Publication Language:** English

**(30) Priority Data:**  
PA 2001 00631 20 April 2001 (20.04.2001) DK

**(71) Applicant (for all designated States except US):**  
NOVOZYMES A/S [DK/DK]; Krogshoejvej 36, DK-2880  
Bagsvaerd (DK).

**(72) Inventors; and**

**(75) Inventors/Applicants (for US only):** **SUGIO, Akiko**  
[JP/US]; 1604 Hillcrest drive Apt. U-21, Manhattan, KS  
66502 (US). **TAKAGI, Shinobu** [JP/JP]; Maehara-nishi  
1-31-1-708, Funabashi, Chiba 274-0825 (JP).

**(74) Common Representative:** NOVOZYMES A/S; Patents,  
Krogshoejvej 36, DK-2880 Bagsvaerd (DK).

**(81) Designated States (national):** AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,  
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,  
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG,  
SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ,  
VN, YU, ZA, ZM, ZW.

**(84) Designated States (regional):** ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),  
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR,  
GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent  
(BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,  
NE, SN, TD, TG).

**Published:**

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



**WO 02/086114 A1**

**(54) Title:** LIPOXYGENASE

**(57) Abstract:** The inventors have found a novel fungal lipoxygenase from Magnaporthe salvinii and determined its sequence. They have sequenced the gene and cloned it into E. coli and deposited the clone. Oligonucleotide probes based on the sequence information are useful for screening a eukaryotic library to obtain a lipoxygenase. The lipoxygenase is useful in baking and in a detergent.

**LIPOXYGENASE****FIELD OF THE INVENTION**

The present invention relates to a lipoxygenase and a polynucleotide encoding it.

**5 BACKGROUND OF THE INVENTION**

Lipoxygenase (EC 1.13.11.12) is an enzyme that catalyzes the oxygenation of poly-unsaturated fatty acids such as linoleic acid, linolenic acid and arachidonic acid, which contain a *cis,cis*-1,4-pentadiene unit and produces hydroperoxides of these fatty acids. The enzyme is widely distributed in plants and animals. A number of lipoxygenase genes have been isolated  
10 from various plant and mammalian sources.

On the other hand, only a limited number of microbial lipoxygenases are known, and no lipoxygenase gene of microbial origin has been described. Su and Oliw, J. Biological Chemistry, 273 (21), 13072-79 (1998) describe a lipoxygenase from *Gaeumannomyces graminis*.

15

**SUMMARY OF THE INVENTION**

The inventors have found a novel fungal lipoxygenase and determined its sequence, which can be used for the production of the enzyme in industrial scale. They have cloned the gene into *E. coli* and deposited the clone.

20 Accordingly, the invention provides a lipoxygenase which is:

a) a polypeptide encoded by a DNA sequence cloned into plasmid pUC19 present in *Escherichia coli* deposited as DSM 14139,

25 b) a polypeptide having an amino acid sequence as the mature peptide shown in SEQ ID NO: 1, or which can be obtained therefrom by substitution, deletion, and/or insertion of one or more amino acids,

c) an analogue of the polypeptide defined in (a) or (b) which:

i) has at least 50 % homology with said polypeptide,

ii) is immunologically reactive with an antibody raised against said

polypeptide in purified form,

30 iii) is an allelic variant of said polypeptide, or

d) a polypeptide encoded by DNA that hybridizes under low stringency conditions with a complementary strand of

i) the DNA sequence cloned into plasmid pUC19 present in *Escherichia coli* deposited as DSM 14139 or

35 ii) the DNA sequence of SEQ ID NO: 1 encoding the mature polypeptide or a subsequence thereof having at least 100 nucleotides.

The invention also provides a polynucleotide which comprises:

- a) the partial DNA sequence encoding a mature lipoxygenase cloned into a plasmid present in *Escherichia coli* DSM 14139,
- b) the partial DNA sequence encoding a mature lipoxygenase shown in SEQ ID NO: 1,
- 5 c) an analogue of the sequence defined in a) or b) which encodes a lipoxygenase and
- i) has at least 60 % homology with said DNA sequence, or
- ii) hybridizes at high stringency with a complementary strand of said DNA sequence or a subsequence thereof having at least 100 nucleotides,
- 10 iii) is an allelic variant thereof, or
- d) a complementary strand of a), b) or c).

Other aspects of the invention provide a nucleic acid construct and a recombinant expression vector comprising the polynucleotide, a recombinant host cell comprising the construct or the vector, and a method of producing a lipoxygenase by cultivating the cell. Further, 15 the invention provides a method of screening a eukaryotic library to obtain a lipoxygenase and an oligonucleotides probe useful for screening. Finally, the invention provides use of the lipoxygenase in baking and in a detergent.

## DETAILED DESCRIPTION OF THE INVENTION

### 20 Genomic DNA source

A lipoxygenase gene of the invention may be derived from a filamentous fungus, e.g. an Ascomycota, particularly Magnaportheaceae, such as a strain of *Magnaporthe*, particularly *Magnaporthe salvinii* Cattaneo (*Mycologia* 64 (1), 110 (1972)). The species is also known under the synonyms *Curvularia sigmoidea*, *Helminthosporium sigmoideum*, *Leptosphaeria salvinii*, *Nakataea sigmoidea*, *Sclerotium oryzae* and *Vakrabeeja sigmoidea*. An example is the strain *M. salvinii* IFO 6642.

Alternatively, the gene may be isolated from *Pyricularia*, e.g. *P. oryzae* or *P. grisea*, e.g. *P. oryzae* IFO 30517. The IFO strains are available on commercial terms from Institute for Fermentation, Osaka (IFO), 17-85, Juso-honmachi 2-chome, Yodogawa-ku, Osaka 532-8686, 30 Japan.

The lipoxygenase gene may be isolated from these organisms using probes designed on the basis of the DNA sequences in this specification.

A strain of *Escherichia coli* containing a lipoxygenase gene from *M. salvinii* IFO 6642 was deposited by the inventors under the terms of the Budapest Treaty with the DSMZ - Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH, Mascheroder Weg 1b, D-38124 Braunschweig DE, Germany. The deposit date was 28 February 2001, and the accession number was DSM 14139.

**Production of lipoxygenase by cultivation of transformant**

The lipoxygenase of the invention may be produced by transforming a suitable host cell with a DNA sequence encoding the lipoxygenase, cultivating the transformed organism under conditions permitting the production of the enzyme, and recovering the enzyme from the culture.

The host organism may be a eukaryotic cell, in particular a fungal cell, such as a yeast cell or a filamentous fungal cell, e.g. a strain of *Aspergillus*, *Fusarium*, *Trichoderma* or *Saccharomyces*, particularly *A. niger*, *A. oryzae*, *F. graminearum*, *F. sambucinum*, *F. cerealis* or *S. cerevisiae*. The production of the lipoxygenase in such host organisms may be done by the general methods described in EP 238,023 (Novo Nordisk), WO 96/00787 (Novo Nordisk) or EP 244,234 (Alko).

**Properties of LOX**

The lipoxygenase of the invention is able to oxidize a wide range of substrates containing a *cis-cis*-pentadienyl moiety. Thus, it acts on polyunsaturated fatty acids such as linoleic acid (18 carbon atoms, 2 double bonds), linolenic acid (18:3), arachidonic acid (20:4), eicosapentaenoic acid (EPA, 20:5) and docosahexaenoic acid (DHA, 22:6). It also acts on substrates other than fatty acids, such as methyl linoleate and probably also triglycerides. The enzyme has a very low Michaelis constant ( $K_M$ ) for linoleic acid and a high specificity ( $V_{max}/K_M$ ) towards this substrate.

The lipoxygenase from *M. salvinii* is a 9-lipoxygenase, i.e. it oxidizes the double bond between carbon atoms 9 and 10 in linoleic acid and linolenic acid.

The lipoxygenase from *M. salvinii* has optimum activity around pH 7, and it is highly active over a broad pH range 3-12, having more than 50 % of optimum activity in the range pH 6-11. It is stable after overnight incubation at pH 5-11.

The native lipoxygenase from *M. salvinii* has optimum activity at 50-60°C. It is quite active at 40-60°C, and the activity begins to decline at 70 °C. The lipoxygenase is stable after 30 minutes incubation at pH 7 at temperatures up to 50°C.

The reaction rate for recombinant lipoxygenase (expressed in *A. oryzae*) increases nearly ten times at the optimal temperature for catalysis compared to the rate obtained at room temperature. The maximum reaction rate is obtained at 67.5°C. A steep decrease in rate constant is seen above the temperature optimum. It is believed that glycosylation renders the recombinant enzyme more stable towards heat than the wild-type enzyme.

The recombinant lipoxygenase is quite stable at temperatures up to 50°C for at least one hour. The activity drops in a linear fashion at higher temperatures between 50-60°C, and no activity is detected after incubations above 60°C for one hour. No activity loss is detected during incubation at temperatures below 45°C.

Frozen solutions of the lipoxygenase lose some activity during storage. With addition of 10 % glycerol there is no discernible activity loss after two weeks storage at -20°C, and the enzyme survived repeated cycles of thaw-freeze without loss of activity.

5 The lipoxygenase of the invention has good stability in the presence of anionic surfactants. Thus, the lipoxygenase from *M. salvinii* is stable in the presence of 400 ppm of LAS (linear alkyl-benzene sulfonate).

### Use of lipoxygenase

10 The lipoxygenase can be used for green flavor synthesis, e.g. nonenal from 9-hydroperoxide of linolenic acid. The synthesis may be done in analogy with Whitehead et al.1995, Cereal foods world 40(4), 193-197 and US 4769243.

The lipoxygenase can also be used for plant hormone synthesis as described in JP H11-29410.

15 Also the lipoxygenase is a good oxidant of carotenoids, so it can be used for bleaching of foodstuffs such as flour, oil or marine food including carotenoids or carotenoid-like pigments.

20 The oxidation activity can be utilized for cross-linking of protein, oil, starch, fiber and mixture of these. Cross-linking of chemical compounds can be utilized for synthesis of polymer to give plastic fiber or plastic resin. It can be used for bleaching as a detergent for phenolic, carotenoid or fatty stains or dinginess. Or it can be used for bleaching of waste water or textile dye.

25 Lipoxygenase can be used for bleaching of plant or marine food materials containing of carotenoids. Thus it could be used for bleaching of flour for bread, noodle or pasta, or bleaching of fish meat or fish oil containing astaxanthin.

30 It also can be used for cross-linking of protein, oil, starch, plant-fiber or mixture of these in presence of fatty acid, oil or fats. It is useful to change the texture or physical properties of foodstuff or to control of flavor for fat and oil, or to produce polymers made of natural staff beside food use. Cross-linked compounds can be chemical compounds, e.g. phenolic, carbonyl, carboxyl or amide compounds or mixture of these. It could be used for synthesis of plastic fiber or resin.

35 Other usages of lipoxygenase can be the synthesis of flavor compound such as hexanal or hexenal together as synergy effect of hydroperoxide lyase. Or in case plant material is used as the source of above two enzymes, lipoxygenase can be added to it to improve the yield of flavor compound. The similar can be done for synthesis of plant or animal hormones.

Finally it can be used as bleaching agent. It can be used in detergents for bleaching of phenolic, carotenoid, fatty stains or dinginess of clothes. Or it can be used for bleaching of textile dye or dye for pulp industry in waste water or changing of dye texture.

**Recombinant expression vector**

The expression vector of the invention typically includes control sequences encoding a promoter, operator, ribosome binding site, translation initiation signal, and, optionally, a selectable marker, a transcription terminator, a repressor gene or various activator genes. The 5 vector may be an autonomously replicating vector, or it may be integrated into the host cell genome.

**Production by cultivation of transformant**

The lipoxygenase of the invention may be produced by transforming a suitable host 10 cell with a DNA sequence encoding the lipoxygenase, cultivating the transformed organism under conditions permitting the production of the enzyme, and recovering the enzyme from the culture.

The host organism may be a eukaryotic cell, in particular a fungal cell, such as a yeast 15 cell or a filamentous fungal cell, e.g. a strain of *Aspergillus*, *Fusarium*, *Trichoderma* or *Saccharomyces*, particularly *A. niger*, *A. oryzae*, *F. graminearum*, *F. sambucinum*, *F. cerealis* or *S. cerevisiae*. The production of the lipoxygenase in such host organisms may be done by the general methods described in EP 238,023 (Novo Nordisk), WO 96/00787 (Novo Nordisk) or EP 244,234 (Alko).

The enzyme can be purified in one step by cation-exchange chromatography to 20 homogeneity.

**Nucleotide probe**

A nucleotide probe may be designed on the basis of the DNA sequence of SEQ ID NO: 1 or the polypeptide sequence of SEQ ID NO: 2, particularly the mature peptide part. The 25 probe may be used in screening for LOX-encoding DNA as described below.

A synthetic oligonucleotide primer may be prepared by standard techniques (e.g. as described in Sambrook J, Fritsch EF, Maniatis T (1989) Molecular cloning: a laboratory manual (2<sup>nd</sup> edn.) Cold Spring Harbor Laboratory, Cold Spring Harbor, New York) on the basis of the mature part of the amino acid sequence in SEQ ID NO: 2 or the corresponding part of the 30 DNA sequence. It may be a degenerate probe and will typically contain at least 20 nucleotides.

**Screening of eukaryotic DNA library**

A polypeptide with lipoxygenase activity may be obtained by a method comprising: 35  
a) preparing a eukaryotic DNA library,  
b) screening the library to select DNA molecules which hybridize to the probe described above,

- c) transforming host cells with the selected DNA molecules,
- d) cultivating the transformed host cells to express polypeptides encoded by the DNA molecules, and
- e) assaying the expressed polypeptides to select polypeptides having lipoxygenase activity.

5 The eukaryotic DNA library may be prepared by conventional methods. It may include genomic DNA or double-stranded cDNA derived from suitable sources such as those described above.

10 Molecular screening for DNA sequences may be carried out by polymerase chain reaction (PCR) followed by hybridization.

In accordance with well-known procedures, the PCR fragment generated in the molecular screening may be isolated and subcloned into a suitable vector. The PCR fragment may be used for screening DNA libraries by e.g. colony or plaque hybridization.

## 15 Hybridization

The hybridization is used to indicate that a given DNA sequence is analogous to a nucleotide probe corresponding to a DNA sequence of the invention. The hybridization may be done at low, medium or high stringency. One example of hybridization conditions is described in detail below.

20 Suitable conditions for determining hybridization between a nucleotide probe and a homologous DNA or RNA sequence involves presoaking of the filter containing the DNA fragments or RNA in 5 x SSC (standard saline citrate) for 10 min, and prehybridization of the filter in a solution of 5 x SSC (Sambrook et al. 1989), 5 x Denhardt's solution (Sambrook et al. 1989), 0.5 % SDS and 100 µg/ml of denatured sonicated salmon sperm DNA (Sambrook et al. 25 1989), followed by hybridization in the same solution containing a random-primed (Feinberg, A. P. and Vogelstein, B. (1983) *Anal. Biochem.* 132:6-13),  $^{32}\text{P}$ -dCTP-labeled (specific activity  $> 1 \times 10^9 \text{ cpm}/\mu\text{g}$ ) probe for 12 hours at approx. 45°C. The filter is then washed two times for 30 minutes in 2 x SSC, 0.5 % SDS at a temperature of at least 55°C, particularly at least 60°C, more particularly at least 65°C, e.g. at least 70°C, or at least 75°C.

30 Molecules to which the oligonucleotide probe hybridizes under these conditions are detected using an x-ray film.

## Alignment and homology

The lipoxygenase and the nucleotide sequence of the invention may have homologies to the disclosed sequences of at least 75 % or at least 85 %, particularly at least 90 % or 35 at least 95 %, e.g. at least 98 %.

For purposes of the present invention, alignments of sequences and calculation of

homology scores were done using a Needleman-Wunsch alignment (i.e. global alignment), useful for both protein and DNA alignments. The default scoring matrices BLOSUM50 and the identity matrix are used for protein and DNA alignments respectively. The penalty for the first residue in a gap is -12 for proteins and -16 for DNA, while the penalty for additional residues in  
5 a gap is -2 for proteins and -4 for DNA. Alignment is from the FASTA package version v20u6 (W. R. Pearson and D. J. Lipman (1988), "Improved Tools for Biological Sequence Analysis", PNAS 85:2444-2448, and W. R. Pearson (1990) "Rapid and Sensitive Sequence Comparison with FASTP and FASTA", Methods in Enzymology, 183:63-98).

## 10 EXAMPLES

### Materials and Methods

Molecular cloning techniques are described in Sambrook et al. (1989).

The following commercial plasmids and *E. coli* strains were used for sub-cloning and DNA library construction:

- 15 pT7Blue (Novagen)  
pUC19 (TOYOBO, Japan)  
*E. coli* JM109 (TOYOBO, Japan)  
*E. coli* DH12S (GIBCO BRL, Life Technologies, USA)

Labeling and detection of hybridization probe was done using DIG-labeling and detection Kit (Boehringer Manheim). Nylon membrane Hybond-N+ (Amersham, England) was  
20 used for DNA transfer for colony hybridization.

Soybean lipoxygenase (type I-B) (cat.# L7315) and astaxanthin (cat.# A-9335) was supplied by Sigma. b-carotene (cat.# 031-05533) were supplied by Wako.

25 Media and buffer solution

COVE-ar: per liter 342.3 g sucrose, 20 ml COVE salt solution, 10 mM acryl amide, 15 mM CsCl<sub>2</sub>, 30 g Agar noble (Difco)

COVE2-ar: per liter 30 g sucrose, 20 ml COVE salt solution, 10 mM acrylamide, 30 g Agar noble (Difco)

30 COVE salt solution: per liter 26 g KCl, 26 g MgSO<sub>4</sub>·7H<sub>2</sub>O, 76 g KH<sub>2</sub>PO<sub>4</sub>, 50ml Cove trace metals.

Cove trace metals: per liter 0.04 g NaB<sub>4</sub>O<sub>7</sub>·10H<sub>2</sub>O, 0.4 g CuSO<sub>4</sub>·5H<sub>2</sub>O, 1.2 g FeSO<sub>4</sub>·7H<sub>2</sub>O, 0.7 g MnSO<sub>4</sub>·H<sub>2</sub>O, 0.7 g Na<sub>2</sub>MoO<sub>2</sub>·2H<sub>2</sub>O, 0.7 g ZnSO<sub>4</sub>·7H<sub>2</sub>O.

AMG trace metals: per liter 14.3 g ZnSO<sub>4</sub>·7H<sub>2</sub>O, 2.5 g CuSO<sub>4</sub>·5H<sub>2</sub>O, 0.5 g NiCl<sub>2</sub>, 13.8  
35 g FeSO<sub>4</sub>, 8.5 g MnSO<sub>4</sub>, 3.0 g citric acid.

YPG: per liter 4 g yeast extract, 1 g KH<sub>2</sub>PO<sub>4</sub>, 0.5 g MgSO<sub>4</sub>·7H<sub>2</sub>O, 15 g glucose, pH 6.0.

STC: 0.8 M Sorbitol, 25 mM Tris pH 8, 25 mM CaCl<sub>2</sub>.

STPC: 40% PEG4000 in STC buffer.

Cove top agarose: per liter 342.3 g sucrose, 20 ml COVE salt solution, 10 mM Acetamide, 10 g low melt agarose.

5 MS-9: per liter 30 g soybean powder, 20 g glycerol, pH 6.0.

MDU-2Bp: per liter 45 g maltose-1H<sub>2</sub>O, 7 g yeast extract, 12 g KH<sub>2</sub>PO<sub>4</sub>, 1 g MgSO<sub>4</sub>-7H<sub>2</sub>O, 2 g K<sub>2</sub>SO<sub>4</sub>, 5 g Urea, 1 g NaCl, 0.5 ml AMG trace metal solution pH 5.0.

#### Host organism

10 *Aspergillus oryzae* BECh2 is described in WO 00/39322. It is a mutant of JaL228 (described in WO98/123000), which is a mutant of IFO4177.

#### Transformation of *A. oryzae*

15 *Aspergillus oryzae* strain BECh2 was inoculated in 100 ml of YPG medium and incubated at 32°C for 16 hours with stirring at 80 rpm. Grown mycelia was collected by filtration followed by washing with 0.6 M KCl and re-suspended in 30 ml of 0.6 M KCl containing Glu-  
canex® (Novozymes) at the concentration of 30 µl/ml. The mixture was incubated at 32°C with the agitation at 60 rpm until protoplasts were formed. After filtration to remove the remained mycelia, protoplasts were collected by centrifugation and washed with STC buffer twice. The protoplasts were counted with a hematitometer and re-suspended in a solution of  
20 STC:STPC:DMSO (8:2:0.1) to a final concentration of 1.2 x 10<sup>7</sup> protoplasts/ml. About 4 µg of DNA was added to 100 µl of protoplast solution, mixed gently and incubated on ice for 30 minutes. 1 µl STPC buffer was added to the mixture and incubated at 37°C for another 30 minutes. After the addition of 10 ml of Cove top agarose pre-warmed at 50°C, the reaction  
25 mixture was poured onto COVE-ar agar plates. The plates were incubated at 32°C for 5 days.

#### SDS-PAGE

30 SDS polyacrylamide electrophoresis was carried out using the commercialized gel PAGEI AE6000 NPU-7.5L (7.5T%) with the apparatus AE-6400 (Atto, Japan) following the provided protocol. 15 µl of sample was suspended in 15 µl of 2x conc. of sample loading buffer (100 mM Tris-HCl (pH 6.8), 200 mM Dithiothreitol, 4% SDS, 0.2% Bromophenol blue and 20% glycerol) and boiled for 5 minutes. 20 µl of sample solution was applied to a polyacrylamide gel, and subjected for electrophoresis in the running buffer (25 mM Tris, 0.1% SDS, 192 mM Glycine) at 20 mA per gel. Resulting gel was stained with SYPRO Orange and  
35 detected by molecular Imager FX (BIO-RAD).

Assays for lipoxygenase activitySpectrophotometric assay

5 Lipoxygenase activity was determined spectrophotometrically at 25°C by following the formation of hydroperoxides with the absorbance at 234 nm. To 0.98 ml of the buffer (50 mM KH<sub>2</sub>PO<sub>4</sub>/NaHPO<sub>4</sub>, pH 7.0), 10µl of substrate solution (10mM linolenic acid dispersed with 0.2% Tween20) was added and the reaction was started by the addition of 10 µl of enzyme solution. One unit causes an increase in absorbance at 234 nm of 0.001/min.

FOX assay

10 The assay was initiated by the addition of 20 µl enzyme solution to 80 µl of 50 mM each buffer containing 0.7 mM linolenic acid dispersed with 0.02% of Tween 20 using Hisco-tron, and incubated for 10 min. The assay was terminated by the addition of 900 µl of FOX reagent: sulfuric acid (25 mM), xylenol orange(100 µM), iron(II) sulfate (100 µM), butylated hydroxytoluen (4 mM) in methanol:water (9:1). Blanks contained only substrate solution during  
15 the incubation, but enzyme solution was added after the addition of FOX reagent. The yellow color of acidified xylene orange was converted to a blue color by the lipid hydroperoxide-mediated oxidation of Fe<sup>2+</sup> ions with the dye. Absorbance of the Fe<sup>3+</sup> complex at 620 nm was measured 1 hour after the addition of FOX reagent.

20 Bleaching assay

Bleaching effect by lipoxygenase was examined spectrophotometrically at 25°C by following the absorbance at 470 nm. The pigment solution was prepared as follows. 150 ul of stock pigment solution (1mg each pigment in 1ml chloroform) was evaporated to be dry. Then 30 ml of the buffer (50 mM KH<sub>2</sub>PO<sub>4</sub>/NaHPO<sub>4</sub>, pH 7.0) with 0.3% of Tween 20 was added  
25 slowly and the pigment was dissolved. To 0.98 ml of the pigment solution, 10µl of substrate solution (10mM linolenic acid dispersed with 0.2% of Tween20) was added and the reaction was started by the addition of 10 µl of enzyme solution.

**Example 1: Cloning of genomic LOX gene from *M. salvinii***

30 Genomic DNA from *Magnaporthe salvinii* was digested with Sac I and separated on 1.0% agarose gel. Around 2.5 kbp of DNA digestion was recovered from the gel and ligated with BAP treated pUC19 linearized by Sac I. Ligation mixture was transformed into *E. coli* DH12S to construct a partial genomic library. It was screened, and a lipoxygenase-positive *E. coli* colony was isolated and the plasmid, termed pSG28, was recovered. The plasmid pSG28  
35 contained a 2.5 kbp SacI genomic fragment that contained the presumed LOX homologue sequence. The sequence of 1973 bp out of 2.5 kbp is shown as SEQ. ID 1.

Introns were identified and are indicated in SEQ ID NO: 1. The splice sites were pre-

dicted as described in S.M. Hebsgaard et al., Nucleic Acids Research, 1996, Vol. 24, No. 17, 3439-3452.

The presumed open reading frame consisted of 1851 bp, and the deduced amino acid sequence corresponded to 617 amino acids, shown as SEQ ID NO: 2. The molecular mass was estimated as 67500 Da.

The *E. coli* DH12S harboring plasmid pSG28 was deposited at DSMZ as DSM 14139 with the accession date 2001-02-28.

### **Example 2: Expression of *M. salvinii* LOX in *A. oryzae***

10

#### Construction of expression plasmid

The partial genomic sequence of *M. salvinii* genomic gene was amplified by PCR using pSG28 as a template. Primer 3 and 4 (SEQ ID NO: 3 and 4) were designed to make *BamH* I and *Xho* I sites at both ends of the PCR product (nucleotides 4-9 of primer 3 and 5-10 of primer 4, respectively). PCR reaction mixture comprised of 2.5 mM dNTP, 30 pmol each of primer 3 and 4, 5 units of LA taq polymerase (Takara) and supplied GC buffer I. Reaction condition was shown below. LA taq polymerase was added to the reaction mixture after step 1.

Step	Temperature	Time
1	98 °C	10 mins
2	96 °C	20 sec
3	55 °C	45 sec
4	72 °C	30 sec
5	72 °C	10 mins

20

\* Step 2 to Step 4 were repeated 30 times.

PCR amplified 1.9 kb fragment was isolated and cloned into pT7Blue resulting in pSG29.

25

The plasmid pSG29 was digested by *BamH*II and *Xhol* and 1.9 kb of fragment which contained the LOX gene was ligated with pMT2188 digested with *BamH*I and *Xhol*. The plasmid pMT2188 has a modified *Aspergillus niger* neutral amylase promoter, *Aspergillus nidulans* TPI leader sequence, *Aspergillus niger* glucoamylase terminator, *Aspergillus nidulans* amdS gene as a marker for fungal transformation and *S. cerevisiae* ura3 as the marker for *E. coli* transformation. Transformation was done with *E. coli* DB6507 in which pyrF gene is deficient and can be complemented with *S. cerevisiae* Ura3. Resulting plasmid was termed pSG30.

30

Expression of *M. salvinii* LOX in *A. oryzae*

*A. oryzae* BECh2 was transformed with the plasmid pSG30 and selection positive transformants were isolated. Transformants were grown on COVE 2 -ar at 32°C for 5 days and inoculated to 100 ml of MS-9 shaking flask. After the cultivation with vigorous agitation at 5 32°C for 1 day, 3 ml of each culture was transferred to 100 ml of MDU-2Bp in shaking flask to cultivate at 32°C for 3 days. Culture broth was centrifuged at 3500 rpm for 10 minutes and supernatant was collected.

Lipoxygenase activities of the supernatant were determined spectrophotometrically as described before. Positive transformants showed about 100,000U/ml culture broth while 10 untransformed *A. oryzae* BECh2 showed no activity. Culture supernatant was also subjected to SDS-PAGE analysis. Positive transformants showed 80-100kDa smear band which indicated the protein was heavily glycosylated. Untransformed *A. oryzae* BECh2 did not show any significant bands.

15 **Example 3: Substrate specificity of lipoxygenase**

Kinetic parameters for a number of substrates were determined by standard methods for the *M. salvinii* lipoxygenase.

Substrate	V <sub>max</sub> (μmol/min/mg)	K <sub>M</sub> (μM)	V <sub>max</sub> /K <sub>M</sub> (μmol/min/mg/μM)
Linoleic acid	2.63	1	2.557
Na linoleate	2.07	0.41	5.061
Linoelaidic acid	No activity	No activity	No activity
Linolenic acid	1.9	0.4	4.488
Eicosadienoic acid	2.02	11	0.177
Arachidonic acid	2.44	5.5	0.446
Linoleoyl chloride	0.97	12	0.080
Methyl linoleate	0.82	30	0.026
Linoleoyl acetate	0.77	9	0.085
Linoleoyl alcohol	1.4	8	0.175

For comparison, one substrate was also tested with soybean lipoxygenase.

Substrate	$V_{max}$ ( $\mu\text{mol}/\text{min}/\text{mg}$ )	$K_M$ ( $\mu\text{M}$ )	$V_{max}/K_M$ ( $\mu\text{mol}/\text{min}/\text{mg}/\mu\text{M}$ )
Linoleic acid	12.3	230	0.054

### Example 3: pH dependence of lipoxygenase activity

5 The relative activity of the *M. salvinii* lipoxygenase at various pH values was determined by the FOX assay described above, using the following buffers: 50 mM citric acid/sodium citrate (pH 2.21-3.73), KH<sub>2</sub>PO<sub>4</sub>/Na<sub>2</sub>HPO<sub>4</sub> (pH 5.30,6.17), Tris/HCl (pH 7.01,8.02), glycylglycine NaCl/NaOH (pH 9.33-11.0).

pH	Relative Activity (%)
2.21	7.11
2.90	20.6
3.73	27.7
5.30	60.0
6.17	83.7
7.01	100
8.02	92.9
9.33	82.6
11.0	77.7

10

### Example 4: Temperature dependence of lipoxygenase activity

The effect of temperature on the *M. salvinii* lipoxygenase was studied by 10 min incubation at pH 7.0.

15

Temperature	Relative Activity (%)
25	50.1
40	90.0
50	100
60	99.6
70	60.4

**Example 5: Bleaching effect of lipoxygenases**

The bleaching effect of *M. salvinii* LOX was examined. Soybean L1 was included for comparison. β-carotene and astaxanthin were used as pigments.

<b>β-carotene</b>	<b>Time (min)</b>	<b><i>M. salvinii</i></b>	<b>Soybean L1</b>
	0	0.3783	0.3575
	0.4	0.3791	0.3616
	0.8	0.3729	0.3601
	1.2	0.3702	0.362
	1.4	0.3685	0.3602
	1.8	0.3651	0.3602
	2.2	0.3633	0.3595
	2.6	0.3486	0.3595
	3	0.341	0.3594
ΔA470/min		0.0121	0.00005
LOX activity		2.652	1.962

5


<b>Astaxanthin</b>	<b>Time (min.)</b>	<b><i>M. salvinii</i></b>	<b>Soybean L1</b>
	0	0.5292	0.5026
	0.4	0.5244	0.5029
	0.8	0.5177	0.505
	1	0.5166	0.5025
	1.4	0.512	0.5013
	1.8	0.5004	0.4993
	2.2	0.4876	0.4985
	2.6	0.4714	0.4986

	3	0.4566	0.498
<b>ΔA470/min</b>		0.0239	0.0021
<b>LOX activity</b>		2.4952	2.018

The results show that *M. salvinii* LOX bleaches the pigment solutions. Soybean LOX showed little effect on bleaching.

0-1	Form - PCT/RO/134 (EASY) Indications Relating to Deposited Microorganism(s) or Other Biological Material (PCT Rule 13bis)	
0-1-1	Prepared using	PCT-EASY Version 2.92 (updated 01.01.2002)
0-2	International Application No.	
0-3	Applicant's or agent's file reference	10148
1	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
1-1	page	2
1-2	line	36-37
1-3	Identification of Deposit	
1-3-1	Name of depositary institution	DSMZ-Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH
1-3-2	Address of depositary institution	Mascheroder Weg 1b, D-38124 Braunschweig, Germany
1-3-3	Date of deposit	28 February 2001 (28.02.2001)
1-3-4	Accession Number	DSMZ 14139
1-4	Additional Indications	NONE
1-5	Designated States for Which Indications are Made	all designated States
1-6	Separate Furnishing of Indications  These indications will be submitted to the International Bureau later	NONE

## FOR RECEIVING OFFICE USE ONLY

0-4	This form was received with the international application: (yes or no)	YES 
0-4-1	Authorized officer	Marie Louise Rosendal Head Clerk

## FOR INTERNATIONAL BUREAU USE ONLY

0-5	This form was received by the International Bureau on:	
0-5-1	Authorized officer	

**CLAIMS**

1. A lipoxygenase which is:

a) a polypeptide encoded by a DNA sequence cloned into plasmid pUC19 present in *Escherichia coli* deposited as DSM 14139,

5 b) a polypeptide having an amino acid sequence as the mature peptide shown in SEQ ID NO: 1, or which can be obtained therefrom by substitution, deletion, and/or insertion of one or more amino acids,

c) an analogue of the polypeptide defined in (a) or (b) which:

i) has at least 50 % homology with said polypeptide,

10 ii) is immunologically reactive with an antibody raised against said polypeptide in purified form,

iii) is an allelic variant of said polypeptide, or

d) a polypeptide encoded by DNA that hybridizes under low stringency conditions with a complementary strand of

15 i) the DNA sequence cloned into plasmid pUC19 present in *Escherichia coli* deposited as DSM 14139 or

ii) the DNA sequence of SEQ ID NO: 1 encoding the mature polypeptide or a subsequence thereof having at least 100 nucleotides.

20 2. The lipoxygenase of claim 1 which is derived from a filamentous fungus, e.g. an Ascomycota, such as a strain of *Magnaporthe*, particularly *M. salvinii*, more particularly strain IFO 6642.

25 3. DNA comprising a nucleic acid sequence which encodes the lipoxygenase of claim 1 or 2.

4. A polynucleotide which comprises:

a) the partial DNA sequence encoding a mature lipoxygenase cloned into a plasmid present in *Escherichia coli* DSM 14139,

30 b) the partial DNA sequence encoding a mature lipoxygenase shown in SEQ ID NO: 1,

c) an analogue of the sequence defined in a) or b) which encodes a lipoxygenase and

i) has at least 60 % homology with said DNA sequence, or

ii) hybridizes at high stringency with a complementary strand of said DNA sequence or a subsequence thereof having at least 100 nucleotides,

35 iii) is an allelic variant thereof, or

d) a complementary strand of a), b) or c).

5. A nucleic acid construct comprising the nucleic acid sequence of claim 3 or 4 operably linked to one or more control sequences capable of directing the expression of the lipoxygenase in a suitable expression host.
- 5 6. A recombinant expression vector comprising the nucleic acid construct of claim 5, a promoter, and transcriptional and translational stop signals.
7. A recombinant host cell comprising the nucleic acid construct of claim 5 or the vector of claim 6.
- 10 8. A method for producing a lipoxygenase comprising cultivating the host cell of claim 7 under conditions conducive to production of the lipoxygenase, and recovering the lipoxygenase.
- 15 9. An oligonucleotide probe which consists of at least 20 nucleotides and which encodes a partial polypeptide sequence of SEQ ID NO: 2.
10. A method for obtaining a polypeptide with lipoxygenase activity, comprising:
- 20 a) preparing a eukaryotic DNA library,
- b) screening the library to select DNA molecules which hybridize to the probe of claim 9,
- c) transforming host cells with the selected DNA molecules,
- d) cultivating the transformed host cells to express polypeptides encoded by the DNA molecules, and
- 25 e) assaying the expressed polypeptides to select polypeptides having lipoxygenase activity.
11. A method for preparing a dough or a baked product made from dough, comprising adding the lipoxygenase of claim 1 or 2 to the dough.
- 30 12. A dough composition comprising the lipoxygenase of claim 1 or 2.
13. A detergent composition comprising a surfactant and the lipoxygenase of claim 1 or 2.
14. The detergent composition of the preceding claim wherein the surfactant is anionic.
- 35 15. A process for oxidizing a polyunsaturated fatty acid comprising contacting the acid with the lipoxygenase of claim 1 or 2 in the presence of air.

16. Use of the process of the preceding claim for green flavor synthesis or plant hormone synthesis.

10148-WO.ST25  
SEQUENCE LISTING

<110> Novozymes A/S

<120> Lipooxygenase

<130> 10148-WO

<160> 4

<170> PatentIn version 3.1

<210> 1

<211> 1973

<212> DNA

<213> Magnaporthe salvinii

<220>

<221> CDS

<222> (1)..(381)

<223>

<220>

<221> mat\_peptide

<222> (52)..()

<223>

<220>

<221> CDS

<222> (501)..(1970)

<223>

<400> 1  
atg cgc atc gga ctc ttg gcc ttc gcc gtc gcg gcg cgc tat gtg gaa      48  
Met Arg Ile Gly Leu Leu Ala Phe Ala Val Ala Ala Arg Tyr Val Glu  
-15                    -10                    -5

## 10148-WO.ST25

gcg ctg cca gtc gcg agc ggc gaa gaa gtg gcc tcg tcg tcc gct ccg	96
Ala Leu Pro Val Ala Ser Gly Glu Glu Val Ala Ser Ser Ser Ala Pro	
-1 1 5 10 15	
acg acg ctg ccc tcg acg tcg agc agc tct gcg ctt ccc tcc ccg acc	144
Thr Thr Leu Pro Ser Thr Ser Ser Ser Ala Leu Pro Ser Pro Thr	
20 25 30	
aag tac acg ctt ccc cac gag gac ccc aac ccg gaa gcg agg aag gcc	192
Lys Tyr Thr Leu Pro His Glu Asp Pro Asn Pro Glu Ala Arg Lys Ala	
35 40 45	
gag ata gcg tta aag agg gga ggg ttc ctc tac gga ccc tcc acc ctg	240
Glu Ile Ala Leu Lys Arg Gly Gly Phe Leu Tyr Gly Pro Ser Thr Leu	
50 55 60	
ggc cag act acc ttt tac ccc agc ggg acc ctg ggg acc gcc atg tcg	288
Gly Gln Thr Thr Phe Tyr Pro Ser Gly Thr Leu Gly Thr Ala Met Ser	
65 70 75	
caa cgc gac cag gcc ctc tgg ctc agg gat gca gag aac caa acg ata	336
Gln Arg Asp Gln Ala Leu Trp Leu Arg Asp Ala Glu Asn Gln Thr Ile	
80 85 90 95	
aca gcg tat cgt gaa gcc aac gag aca ctg agg gat atc cag agc	381
Thr Ala Tyr Arg Glu Ala Asn Glu Thr Leu Arg Asp Ile Gln Ser	
100 105 110	
gtatgtgtcg agccgtgttt atgcgttcca atcattctct gtgctcctgt ccgtccccgc	441
ccggggttac agccaagccg attcagtagc taactcggaa tgtctggttt gctctgcag	500
cat ggc ggt ctc aag acg ctt gac gac ttc gcg ctc ctc tac gac ggc	548
His Gly Gly Leu Lys Thr Leu Asp Asp Phe Ala Leu Leu Tyr Asp Gly	
115 120 125	
cat tgg aaa gcg tcg gtc cca gag gga ata gaa aag ggc atg ctg agc	596
His Trp Lys Ala Ser Val Pro Glu Gly Ile Glu Lys Gly Met Leu Ser	
130 135 140	
aac tac act tcg gac ctg ctc ttt tcc atg gag cgg ctc tcc aac aac	644
Asn Tyr Thr Ser Asp Leu Leu Phe Ser Met Glu Arg Leu Ser Asn Asn	
145 150 155	
ccc tac agc ctc aag cgc ctc cat cca acc aag gac aag ctg ccg ttc	692
Pro Tyr Ser Leu Lys Arg Leu His Pro Thr Lys Asp Lys Leu Pro Phe	
160 165 170	
agc gtc gag gac aag gtg gtc aag cag ctg acg gcc acg acg ctt gcg	740
Ser Val Glu Asp Lys Val Val Lys Gln Leu Thr Ala Thr Thr Leu Ala	
175 180 185 190	
gcg ctc cac aag gcc ggc cgt ctc ttc ttc gtt gac cac agc gat cag	788
Ala Leu His Lys Ala Gly Arg Leu Phe Phe Val Asp His Ser Asp Gln	
195 200 205	
aag aaa tac acg ccg cag gca ggt cgg tat gct gcg gcc tgc cag ggg	836
Lys Lys Tyr Thr Pro Gln Ala Gly Arg Tyr Ala Ala Ala Cys Gln Gly	
210 215 220	
ctt ttc tat gtg gac gcg cgg tcc aat cag ttc ctg ccg ctg gcc atc	884
Leu Phe Tyr Val Asp Ala Arg Ser Asn Gln Phe Leu Pro Leu Ala Ile	
225 230 235	
aag acc aac gtg ggc gca gac ctg acg tac acg cca ctc gac gac aag	932
Lys Thr Asn Val Gly Ala Asp Leu Thr Tyr Thr Pro Leu Asp Asp Lys	
240 245 250	

## 10148-WO.ST25

aac	gac	tgg	ctt	ctg	gcc	aag	atc	atg	ttc	aac	aac	aat	gac	ctg	ttc		980
Asn	Asp	Trp	Leu	Leu	Ala	Lys	Ile	Met	Phe	Asn	Asn	Asn	Asp	Leu	Phe		
255					260				265						270		
tac	tcg	cag	atg	tac	cat	gtc	ctg	ttc	cac	acg	gtt	cca	gaa	atc	gtg		1028
Tyr	Ser	Gln	Met	Tyr	His	Val	Leu	Phe	His	Thr	Val	Pro	Glu	Ile	Val		
275					280				285							285	
cac	atg	gcc	gcc	atc	cgg	acg	cta	agc	gag	agc	cac	ccg	gtg	ctg	gcc		1076
His	Met	Ala	Ala	Ile	Arg	Thr	Leu	Ser	Glu	Ser	His	Pro	Val	Leu	Ala		
290					295				300								
gtg	ctc	aat	cgg	atc	atg	tat	caa	gcc	tat	gcg	atc	cgg	cca	gtg	ggc		1124
Val	Leu	Asn	Arg	Ile	Met	Tyr	Gln	Ala	Tyr	Ala	Ile	Arg	Pro	Val	Gly		
305					310				315								
gaa	cgc	atc	ctg	ttc	aac	ccg	ggc	ggg	ttt	tgg	gac	cag	aac	ctt	ggc		1172
Glu	Arg	Ile	Leu	Phe	Asn	Pro	Gly	Gly	Phe	Trp	Asp	Gln	Asn	Leu	Gly		
320					325				330								
ctg	ccc	gcc	acg	gcf	gcc	gtc	gac	ttt	ctc	agt	tcc	atc	tac	gcc	cat		1220
Leu	Pro	Ala	Thr	Ala	Ala	Val	Asp	Phe	Leu	Ser	Ser	Ile	Tyr	Ala	His		
335					340				345						350		
ggc	gag	ggc	ggg	ttc	cgg	gcc	ggc	tac	gtg	gaa	aac	aac	ctg	cgc	aag		1268
Gly	Glu	Gly	Gly	Phe	Arg	Ala	Gly	Tyr	Val	Glu	Asn	Asn	Leu	Arg	Lys		
355					360				365								
cgg	ggg	ctg	gtg	ggc	gac	acc	ttt	ggc	ggc	ccg	gcg	ctc	ccg	cac	ttc		1316
Arg	Gly	Leu	Val	Gly	Asp	Thr	Phe	Gly	Gly	Pro	Ala	Leu	Pro	His	Phe		
370					375				380								
ccc	ttc	tac	gag	gac	gcf	cag	cgc	gtc	ctc	ggg	gcf	atc	cgc	ggc	ttc		1364
Pro	Phe	Tyr	Glu	Asp	Ala	Gln	Arg	Val	Leu	Gly	Ala	Ile	Arg	Gly	Phe		
385					390				395								
atg	cag	gcc	ttt	gtc	gac	tcg	acc	tac	ggg	ggc	gac	gac	ggc	gcf	ctg		1412
Met	Gln	Ala	Phe	Val	Asp	Ser	Thr	Tyr	Gly	Gly	Asp	Asp	Gly	Ala	Leu		
400					405				410								
gcf	cgc	gac	ttt	gag	ctg	cag	gac	tgg	gtg	gcc	gag	gcc	aac	ggg	ccg		1460
Ala	Arg	Asp	Phe	Glu	Leu	Gln	Asp	Trp	Val	Ala	Glu	Ala	Asn	Gly	Pro		
415					420				425						430		
gcf	cag	gtg	cgc	gac	ttc	ccc	acg	gcf	ccg	ctg	cgf	cgf	cgc	gag	gag		1508
Ala	Gln	Val	Arg	Asp	Phe	Pro	Thr	Ala	Pro	Leu	Arg	Arg	Arg	Glu	Glu		
435					440				445								
ctg	gtg	ggc	atc	ctg	acg	cac	ata	gcc	tgg	aac	acg	ggc	ggc	gcf	cac		1556
Leu	Val	Gly	Ile	Leu	Thr	His	Ile	Ala	Trp	Asn	Thr	Gly	Gly	Ala	His		
450					455				460								
cac	gtt	cta	aac	cag	ggg	gcf	ccc	gtg	cgc	gcc	tcg	ggc	gtg	ctg	ccg		1604
His	Val	Leu	Asn	Gln	Gly	Ala	Pro	Val	Arg	Ala	Ser	Gly	Val	Leu	Pro		
465					470				475								
ctc	cac	ccg	gcf	gct	ctt	tac	gcf	ccc	gtc	ccg	gcf	gcc	aag	ggc	gcc		1652
Leu	His	Pro	Ala	Ala	Leu	Tyr	Ala	Pro	Val	Pro	Ala	Ala	Lys	Gly	Ala		
480					485				490								
gtc	gcf	tcc	agc	gac	ggc	ctg	ctg	gcf	tgg	ctg	ccg	gac	gag	gtc	aaa		1700
Val	Ala	Ser	Ser	Asp	Gly	Leu	Leu	Ala	Trp	Leu	Pro	Asp	Glu	Val	Lys		
495					500				505						510		
tcg	gtg	gag	cag	gtg	tcg	ctg	ctg	gcf	cgc	tcc	aac	cgc	gcf	cag	gtt		1748
Ser	Val	Glu	Gln	Val	Ser	Leu	Leu	Ala	Arg	Phe	Asn	Arg	Ala	Gln	Val		
515					520				525								

## 10148-WO.ST25

agg gac aga aac cag acg gtg cgc aac atg ttc gcc gca ccg gag ctg	1796
Arg Asp Arg Asn Gln Thr Val Arg Asn Met Phe Ala Ala Pro Glu Leu	
530 535 540	
ctg gct gga aat ggc gag gcg tac gcg gcg gcc aac gcg agg ttc gtc	1844
Leu Ala Gly Asn Gly Glu Ala Tyr Ala Ala Ala Asn Ala Arg Phe Val	
545 550 555	
gag gag acg ggc cgg ata agc cgc gag ata gag ggc agg ggt ttc gat	1892
Glu Glu Thr Gly Arg Ile Ser Arg Glu Ile Glu Gly Arg Gly Phe Asp	
560 565 570	
agc aag ggc ctg agc cag ggg atg ccc ttt atc tgg acc gcc ttg aat	1940
Ser Lys Gly Leu Ser Gln Gly Met Pro Phe Ile Trp Thr Ala Leu Asn	
575 580 585 590	
ccc gcg gtg aac ccg ttt ttc ctg agc atc tag	1973
Pro Ala Val Asn Pro Phe Leu Ser Ile	
595 600	

&lt;210&gt; 2

&lt;211&gt; 617

&lt;212&gt; PRT

&lt;213&gt; Magnaporthe salvinii

&lt;400&gt; 2

Met Arg Ile Gly Leu Leu Ala Phe Ala Val Ala Ala Arg Tyr Val Glu			
-15	-10		-5
	-5		

Ala Leu Pro Val Ala Ser Gly Glu Glu Val Ala Ser Ser Ser Ala Pro					
-1 1	5		10		15
	10		15		
	15				

Thr Thr Leu Pro Ser Thr Ser Ser Ser Ala Leu Pro Ser Pro Thr			
20	25		30
	30		

Lys Tyr Thr Leu Pro His Glu Asp Pro Asn Pro Glu Ala Arg Lys Ala			
35	40		45
	45		

Glu Ile Ala Leu Lys Arg Gly Gly Phe Leu Tyr Gly Pro Ser Thr Leu			
50	55		60
	60		

Gly Gln Thr Thr Phe Tyr Pro Ser Gly Thr Leu Gly Thr Ala Met Ser			
65	70		75
	75		

Gln Arg Asp Gln Ala Leu Trp Leu Arg Asp Ala Glu Asn Gln Thr Ile					
80	85		90		95
	90		95		
	95				

Thr Ala Tyr Arg Glu Ala Asn Glu Thr Leu Arg Asp Ile Gln Ser His			
100	105		110
	110		

Gly Gly Leu Lys Thr Leu Asp Asp Phe Ala Leu Leu Tyr Asp Gly His			
115	120		125
	125		

10148-WO.ST25

Trp Lys Ala Ser Val Pro Glu Gly Ile Glu Lys Gly Met Leu Ser Asn  
 130 135 140

Tyr Thr Ser Asp Leu Leu Phe Ser Met Glu Arg Leu Ser Asn Asn Pro  
 145 150 155

Tyr Ser Leu Lys Arg Leu His Pro Thr Lys Asp Lys Leu Pro Phe Ser  
 160 165 170 175

Val Glu Asp Lys Val Val Lys Gln Leu Thr Ala Thr Thr Leu Ala Ala  
 180 185 190

Leu His Lys Ala Gly Arg Leu Phe Phe Val Asp His Ser Asp Gln Lys  
 195 200 205

Lys Tyr Thr Pro Gln Ala Gly Arg Tyr Ala Ala Ala Cys Gln Gly Leu  
 210 215 220

Phe Tyr Val Asp Ala Arg Ser Asn Gln Phe Leu Pro Leu Ala Ile Lys  
 225 230 235

Thr Asn Val Gly Ala Asp Leu Thr Tyr Thr Pro Leu Asp Asp Lys Asn  
 240 245 250 255

Asp Trp Leu Leu Ala Lys Ile Met Phe Asn Asn Asn Asp Leu Phe Tyr  
 260 265 270

Ser Gln Met Tyr His Val Leu Phe His Thr Val Pro Glu Ile Val His  
 275 280 285

Met Ala Ala Ile Arg Thr Leu Ser Glu Ser His Pro Val Leu Ala Val  
 290 295 300

Leu Asn Arg Ile Met Tyr Gln Ala Tyr Ala Ile Arg Pro Val Gly Glu  
 305 310 315

Arg Ile Leu Phe Asn Pro Gly Gly Phe Trp Asp Gln Asn Leu Gly Leu  
 320 325 330 335

Pro Ala Thr Ala Ala Val Asp Phe Leu Ser Ser Ile Tyr Ala His Gly  
 340 345 350

Glu Gly Gly Phe Arg Ala Gly Tyr Val Glu Asn Asn Leu Arg Lys Arg  
 355 360 365

Gly Leu Val Gly Asp Thr Phe Gly Gly Pro Ala Leu Pro His Phe Pro  
 370 375 380

Phe Tyr Glu Asp Ala Gln Arg Val Leu Gly Ala Ile Arg Gly Phe Met  
 385 390 395

10148-WO.ST25

Gln Ala Phe Val Asp Ser Thr Tyr Gly Gly Asp Asp Gly Ala Leu Ala  
400 405 410 415

Arg Asp Phe Glu Leu Gln Asp Trp Val Ala Glu Ala Asn Gly Pro Ala  
420 425 430

Gln Val Arg Asp Phe Pro Thr Ala Pro Leu Arg Arg Arg Glu Glu Leu  
435 440 445

Val Gly Ile Leu Thr His Ile Ala Trp Asn Thr Gly Gly Ala His His  
450 455 460

Val Leu Asn Gln Gly Ala Pro Val Arg Ala Ser Gly Val Leu Pro Leu  
465 470 475

His Pro Ala Ala Leu Tyr Ala Pro Val Pro Ala Ala Lys Gly Ala Val  
480 485 490 495

Ala Ser Ser Asp Gly Leu Leu Ala Trp Leu Pro Asp Glu Val Lys Ser  
500 505 510

Val Glu Gln Val Ser Leu Leu Ala Arg Phe Asn Arg Ala Gln Val Arg  
515 520 525

Asp Arg Asn Gln Thr Val Arg Asn Met Phe Ala Ala Pro Glu Leu Leu  
530 535 540

Ala Gly Asn Gly Glu Ala Tyr Ala Ala Ala Asn Ala Arg Phe Val Glu  
545 550 555

Glu Thr Gly Arg Ile Ser Arg Glu Ile Glu Gly Arg Gly Phe Asp Ser  
560 565 570 575

Lys Gly Leu Ser Gln Gly Met Pro Phe Ile Trp Thr Ala Leu Asn Pro  
580 585 590

Ala Val Asn Pro Phe Phe Leu Ser Ile  
595 600

<210> 3

<211> 29

<212> DNA

<213> Artificial/Unknown

<220>

<221> misc\_feature

10148-WO.ST25

&lt;223&gt; Artificial

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Primer 3

<400> 3  
cgccgatcca tgcgcatcg actcttggc

29

&lt;210&gt; 4

&lt;211&gt; 31

&lt;212&gt; DNA

&lt;213&gt; Artificial/Unknown

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Artificial

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Primer 4

<400> 4  
cccgctcgag ctagatgctc aggaaaaacg g

31

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/DK 02/00251

A. CLASSIFICATION OF SUBJECT MATTER				
IPC 7	C12N9/02	A21D8/04	C12P7/64	C12N15/63
				C11D3/386

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)  
IPC 7 C12N A21D C12P C11D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

PAJ, EPO-Internal, SEQUENCE SEARCH

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	WO 02 20730 A (NOVOZYMES AS) 14 March 2002 (2002-03-14) claims 1-17 & DATABASE EBI [Online] retrieved from EBI Database accession no. ax398040 77% identity in 618 aa overlap with SEQ ID No.2 --- WO 00 60093 A (INST PFLANZENBIOCHEMIE IPB (DE)) 12 October 2000 (2000-10-12) claims 1-14 --- -/--	1-8, 10-16
A		1-8, 10-16

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

° Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority, claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
1 August 2002	15.08.2002
Name and mailing address of the ISA	Authorized officer

European Patent Office, P.B. 5818 Patentlaan 2  
 NL - 2280 HV Rijswijk  
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.  
 Fax: (+31-70) 340-3016

ekström nils

## INTERNATIONAL SEARCH REPORT

International Application No  
PCT/DK 02/00251

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	PATENT ABSTRACTS OF JAPAN vol. 2000, no. 07, 29 September 2000 (2000-09-29) & JP 2000 106832 A (HONEN CORP), 18 April 2000 (2000-04-18) abstract; claims 1-5 ---	1-8, 10-16
A	US 6 204 037 B1 (BRASH A R ET AL) 20 March 2001 (2001-03-20) claims 1-22 ---	1-8, 10-16
P,A	WO 01 29227 A (BASF AG) 26 April 2001 (2001-04-26) claims 1-20 ---	1-8, 10-16
P,A	WO 01 79560 A (GLAXO GROUP LTD ;EDWARDS LISA D (US); EMMETT AMANDA H (US); ANDERS) 25 October 2001 (2001-10-25) claims 1-31 ---	1-8, 10-16
P,A	WO 01 90323 A (MILLENNIUM PHARM INC (US)) 29 November 2001 (2001-11-29) claims 1-22 ---	1-8, 10-16
P,A	HÖRNSTEN L ET AL: "Cloning of the manganese lipoxygenase gene reveals homology with the lipoxygenase gene family." EUR. J. BIOCHEM., vol. 269, 2002, pages 2690-2697, XP002902589 the whole document -----	1-8, 10-16

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/DK 02/00251

### Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1.  Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
  
2.  Claims Nos.: 9 because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:  
see FURTHER INFORMATION sheet PCT/ISA/210
  
3.  Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

### Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1.  As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
  
2.  As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
  
3.  As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
  
4.  No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

#### Remark on Protest

- The additional search fees were accompanied by the applicant's protest.  
 No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 9

Claim 9 relates to oligonucleotid consisting of at least 20 nucleotides and encodes a partial polypeptide of SEQ. ID. No. 2. These polypeptides are 601 amino acids long- encoded by more than 1800 nucleotides; claim 9 covers a large number of possibilities. In view of the large number of possibilities- not limited even by a general functionality- render it difficult, if not impossible, to determine the matter for which protection is sought. The present claim fails to comply with the clarity and conciseness requirements of Article 6 PCT to such extent that a meaningful search is impossible. As a consequence of this, claim 9 has not been searched.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

## INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/DK 02/00251

Patent document cited in search report		Publication date		Patent family member(s)		Publication date
WO 0220730	A	14-03-2002	AU WO	8571901 A 0220730 A2	22-03-2002 14-03-2002	
WO 0060093	A	12-10-2000	DE AU WO EP	19914464 A1 3557700 A 0060093 A1 1165801 A1	05-10-2000 23-10-2000 12-10-2000 02-01-2002	
JP 2000106832	A	18-04-2000	NONE			
US 6204037	B1	20-03-2001	US	2001046672 A1	29-11-2001	
WO 0129227	A	26-04-2001	DE AU WO EP NO	19950921 A1 1023501 A 0129227 A1 1222282 A1 20021851 A	26-04-2001 30-04-2001 26-04-2001 17-07-2002 03-06-2002	
WO 0179560	A	25-10-2001	AU WO	5166501 A 0179560 A2	30-10-2001 25-10-2001	
WO 0190323	A	29-11-2001	AU WO	6475301 A 0190323 A2	03-12-2001 29-11-2001	